Diagnostic and prognostic values of KRAS mutations on EUS-FNA specimens and circulating tumor DNA in patients with pancreatic cancer

• DOI: 10.21203/rs.2.20563/v1
• Publication Date: 2020-01-10T16:59:16Z
• Authors: Ronghua Wang; Jinlin Wang; Yuchong Zhao; Yun Wang; Zhenxiong Zhao; Qian Chen; Yaqi Duan; Bin Cheng
• Keywords: Endoscopic Ultrasound

Abstract Background: Early diagnosis is critical in reducing pancreatic cancer mortality. We explore the diagnostic values of detecting KRAS gene mutations and plasma circulating tumor DNA (ctDNA) patients with primary cancer. Methods: The cohort study comprised 149 consecutive solid mass underwent Endoscopic ultrasound fine needle aspiration (EUS-FNA) between September, 2014 May, 2016. point (G12V, G12D, G12R) were analyzed by droplet digital PCR (ddPCR) EUS-guided (FNA) histopathology tissue samples blood tested for ctDNA. final was based on surgical resection pathology or follow up at least 2 years. Results: sensitivity accuracy EUS-FNA diagnose increased from 71.4% to 91.6% (P<0.001) 75.8% 88.6% (P <0.001), respectively, when mutation ddPCR analysis added standard assessment. biomarkers combination (ctDNA CA19-9) 78.9% 76.2%, respectively. median survival time significantly shorter G12D (180 days) compared other (240 (long-rank test, P<0.001). Conclusions: tissues improves cyto/histopathological evaluation samples. obviously higher than non-invasive blood-based ctDNA independently associated poor overall survival.